Comparative Pharmacology
Head-to-head clinical analysis: POLYTRIM versus RAXAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POLYTRIM versus RAXAR.
POLYTRIM vs RAXAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Polymyxin B sulfate binds to the lipopolysaccharide (LPS) in the outer membrane of Gram-negative bacteria, disrupting membrane integrity and causing cell death. Trimethoprim inhibits bacterial dihydrofolate reductase, blocking the conversion of dihydrofolic acid to tetrahydrofolic acid, thereby inhibiting bacterial DNA synthesis.
RAXAR (revumenib) is a selective inhibitor of the menin-KMT2A protein-protein interaction. By binding to menin, it blocks the interaction with KMT2A (MLL1), thereby disrupting the transcription of oncogenic genes such as HOXA9 and MEIS1, leading to differentiation and apoptosis of leukemic cells.
1 drop in the affected eye(s) every 4 hours for 7-10 days.
Subcutaneous injection: 200 mg once daily, irrespective of timing of meals.
None Documented
None Documented
Terminal elimination half-life of polymyxin B is 4.5-6 hours; for trimethoprim it is 8-10 hours. In renal impairment, half-life of both components is prolonged.
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged in hepatic impairment (up to 25 hours).
Renal excretion accounts for approximately 40% of the dose as unchanged polymyxin B and 60% as unchanged trimethoprim. Biliary/fecal elimination is minimal (<5% for each component).
Primarily hepatic metabolism; renal excretion of unchanged drug <5%; biliary/fecal elimination as metabolites accounts for >90% of total clearance.
Category C
Category C
Ophthalmic Antibiotic
Ophthalmic Antibiotic